Department of Radiology, Huashan Hospital, Fudan University, No. 12 Wulumuqi Road (Middle), Shanghai, 200040, China.
Institute of Functional and Molecular Medical Imaging, Fudan University, No. 12 Wulumuqi Road (Middle), Shanghai, 200040, China.
J Thromb Thrombolysis. 2019 Jul;48(1):68-76. doi: 10.1007/s11239-019-01865-2.
Patients with carotid atherosclerosis, especially the elderly population, take antithrombotic medicine regularly. However, no previous meta-analysis has focused on one of the possible side effects of such drugs, namely intraplaque hemorrhage (IPH). To determine whether antiplatelet drugs or anticoagulants are associated with an increased risk of carotid IPH. We searched Pubmed, Embase, Ovid MEDLINE, Cochrane Library for relevant studies that were published in English, from January 1st, 1989 to January 1st, 2019. We pooled the odds ratio (OR) with 95% confidence interval (CI) from individual studies and conducted quality assessment, heterogeneity, publication bias analysis and sensitivity analysis. A total of four cross-sectional studies, involving 2714 participants with carotid atherosclerotic plaques was included into this meta-analysis. We found a significant association between the use of anticoagulants and higher risk of carotid IPH (OR 1.95; 95% CI 1.16-3.30, P = 0.92; I = 0). No significant association was found between the use of antiplatelet drugs and increased risk of carotid IPH (OR 1.34; 95% CI 0.68-2.61, P = 0.03; I = 65%). Our meta-analysis reveals that it is the use of oral anticoagulants rather than antiplatelet drugs that may be associated with an increased risk of carotid IPH in atherosclerosis patients.
患有颈动脉粥样硬化的患者,尤其是老年人群,需要定期服用抗血栓药物。然而,以前的荟萃分析并未关注此类药物的一种可能的副作用,即斑块内出血(IPH)。为了确定抗血小板药物或抗凝剂是否会增加颈动脉 IPH 的风险。我们检索了 Pubmed、Embase、Ovid MEDLINE、Cochrane Library 中 1989 年 1 月 1 日至 2019 年 1 月 1 日发表的英文相关研究。我们从个体研究中汇总了比值比(OR)及其 95%置信区间(CI),并进行了质量评估、异质性、发表偏倚分析和敏感性分析。共有四项横断面研究,共纳入 2714 例颈动脉粥样硬化斑块患者。我们发现抗凝剂的使用与颈动脉 IPH 的风险增加之间存在显著关联(OR 1.95;95%CI 1.16-3.30,P=0.92;I=0)。抗血小板药物的使用与颈动脉 IPH 风险增加之间无显著关联(OR 1.34;95%CI 0.68-2.61,P=0.03;I=65%)。我们的荟萃分析表明,可能是口服抗凝剂的使用而不是抗血小板药物的使用与动脉粥样硬化患者颈动脉 IPH 的风险增加相关。